APA (7th ed.) Citation

Mougalian, S. S., Copher, R., Kish, J. K., McAllister, L., Wang, Z., Broscious, M., . . . Feinberg, B. A. (2018, September). Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting. Cancer Medicine.

Chicago Style (17th ed.) Citation

Mougalian, Sarah S., Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, and Bruce A. Feinberg. "Clinical Benefit of Treatment with Eribulin Mesylate for Metastatic Triple‐negative Breast Cancer: Long‐term Outcomes of Patients Treated in the US Community Oncology Setting." Cancer Medicine Sep. 2018.

MLA (9th ed.) Citation

Mougalian, Sarah S., et al. "Clinical Benefit of Treatment with Eribulin Mesylate for Metastatic Triple‐negative Breast Cancer: Long‐term Outcomes of Patients Treated in the US Community Oncology Setting." Cancer Medicine, Sep. 2018.